Jiangsu Hengrui Medicine
600276.SS
#531
Rank
C$67.93 B
Marketcap
C$10.24
Share price
-0.60%
Change (1 day)
-16.22%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

EPS for Jiangsu Hengrui Medicine (600276.SS)

EPS in 2023 (TTM): C$0.12

According to Jiangsu Hengrui Medicine 's latest financial reports the company's current EPS (TTM) is C$0.21. In 2022 the company made an earnings per share (EPS) of C$0.13 a decrease over its 2021 EPS that were of C$0.16.

EPS history for Jiangsu Hengrui Medicine from 2002 to 2023

Annual EPS

Year EPS Change
2023 (TTM)C$0.12-4.83%
2022C$0.13-17.1%
2021C$0.16-24.44%
2020C$0.2120.3%
2019C$0.1725.58%
2018C$0.1427.55%
2017C$0.1121.64%
2016C$0.0880013.57%
2015C$0.0774839.86%
2014C$0.0554021.33%
2013C$0.0456617.7%
2012C$0.0387925.56%
2011C$0.0309026.22%
2010C$0.0244810.3%
2009C$0.0221957.92%
2008C$0.0140511.06%
2007C$0.0126585.81%
2006C$0.00681087.94%
2005C$0.00362333.97%
2004C$0.00270429.78%
2003C$0.00208419.78%
2002C$0.001740